RT Journal Article
SR Electronic
T1 Acupuncture at Sanyinjiao(SP6) for patients with primary dysmenorrhea: Protocol for a systematic review and meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.24.23296053
DO 10.1101/2023.09.24.23296053
A1 Wang, Xuemei
A1 Yang, Jiao
A1 Liu, Jing
A1 Yang, Yepeng
A1 Zhang, Zhiyuan
A1 Xie, Ping
YR 2023
UL http://medrxiv.org/content/early/2023/09/26/2023.09.24.23296053.abstract
AB Background Primary dysmenorrhea (PD) is a gynecological disease that seriously affects women’s physical and mental health and quality of life. Sanyinjiao (SP6) is the most used acupoint for acupuncture treatment of PD, and acupuncture SP6 is more commonly used in the clinical treatment of PD, but evidence of effectiveness and safety is lacking. The purpose of this systematic review plan is to develop a study protocol that can evaluate the efficacy and safety of acupuncture SP6 in the treatment of PD.Methods The upper limit of retrieval time will be set to September 2023. Foreign and Chinese databases will be searched respectively: Cochrane Library, PubMed, EMBASE, Ovid, Korea Med, J-Global, J-Stage databases, and CNKI, CBM, SinoMed, VIP, Wanfang. Randomized controlled trials meeting the inclusion criteria will be screened by two independent reviewers, and data extraction and risk of bias assessment will be carried out. The primary outcome is dysmenorrhea symptoms, and the secondary outcomes include recent clinical cure rate, concomitant symptoms, serum prostaglandins, uterine artery blood flow resistance under ultrasound monitoring, and adverse reactions. Use RevMan V.5.3 software to perform the following operations: data synthesis, subgroup analysis, heterogeneity analysis, and sensitivity analysis. The evidence quality of clinical studies included in this study will be evaluated by the software of “Grading of Recommendations Assessment, Development, and Evaluation”.Results This study will provide comprehensive clinical evidence for treating PD with acupuncture SP6.Conclusion This systematic review will confirm whether acupuncture SP6 is safe and effective in treating PD clinically.Registration details PROSPERO CRD42020171664.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.crd.york.ac.uk/PROSPERO/ Funding StatementThis study is funded by the National Science Foundation of China (No. 82374512,81674017), http://www.nsfc.gov.cn/.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAfter the completion of the systematic review, all the data extracted from the literature will be published with the publication of the article.PDPrimary Dysmenorrhea,SP6Sanyinjiao,VASVisual analogue scale,TCMTraditional Chinese Medicine.LOCFLast Observation Carried forward,NSAIDsNonsteroidal Antiinflammatory Drugs,WCAWorst Case Analysis.